Sorafenib-Loaded Silica-Containing Redox Nanoparticle Decreases Tumorigenic Potential of Lewis Lung Carcinoma
<b>Background:</b> Orally administered sorafenib has shown limited improvement in overall survival for non-small-cell lung cancer patients, likely due to poor pharmacokinetics and adverse effects, including gastrointestinal toxicity. To address these issues, we developed silica-containin...
Saved in:
Main Authors: | Babita Shashni, Hao Thi Tran, Long Binh Vong, Ren-Jei Chung, Yukio Nagasaki |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2025-01-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/17/1/50 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Transcription Factor Creb is Involved in Sorafenib-Inhibited Renal Cancer Cell Proliferation, Migration and Invasion
by: Huang Shuaishuai, et al.
Published: (2018-12-01) -
Phase II study with sorafenib plus radiotherapy for advanced HCC with portal and/or hepatic vein tumor thrombosis
by: Yirui Zhai, et al.
Published: (2025-03-01) -
Lenvatinib versus sorafenib as second-line therapy following progression on atezolizumab–bevacizumab in patients with unresectable hepatocellular carcinoma: a multicenter retrospective study from Korea and Japan
by: Jaekyung Cheon, et al.
Published: (2025-01-01) -
Sorafenib enhanced the function of myeloid-derived suppressor cells in hepatocellular carcinoma by facilitating PPARα-mediated fatty acid oxidation
by: Chunxiao Li, et al.
Published: (2025-01-01) -
ANGPTL3 overcomes sorafenib resistance via suppression of SNAI1 and CPT1A in liver cancer
by: Yang-Hsiang Lin, et al.
Published: (2025-02-01)